Pegylated Interferon Alpha-2b for Patients with HCV Recurrence and Graft Fibrosis Following Liver Transplantation
Open Access
- 1 April 2006
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Transplantation
- Vol. 6 (4), 825-833
- https://doi.org/10.1111/j.1600-6143.2006.01255.x
Abstract
No abstract availableKeywords
This publication has 47 references indexed in Scilit:
- Combined treatment with pegylated interferon (α-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantationJournal of Hepatology, 2005
- Pegylated versus standard interferon‐α in antiviral regimens for post‐transplant recurrent hepatitis C: Comparison of tolerability and efficacyJournal of Gastroenterology and Hepatology, 2005
- Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis CTransplant International, 2004
- Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infectionLiver Transplantation, 2004
- Hepatitis C, interferon, and risk of rejection after liver transplantationLiver Transplantation, 2004
- Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinationJournal of Hepatology, 2004
- Treatment of hepatitis C virus infection in the allograftLiver Transplantation, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Hepatitis C Virus InfectionNew England Journal of Medicine, 2001
- Long-Term Outcome of Hepatitis C Infection after Liver TransplantationNew England Journal of Medicine, 1996